{"id":"NCT00057681","sponsor":"Washington University School of Medicine","briefTitle":"Study of Outcome and Safety of Lithium, Divalproex and Risperidone for Mania in Children and Adolescents","officialTitle":"Treatment of Early Age Mania (TEAM) Study","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2003-02","primaryCompletion":"2008-12","completion":"2008-12","firstPosted":"2003-04-07","resultsPosted":"2013-03-27","lastUpdate":"2013-04-04"},"enrollment":379,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Bipolar Disorder"],"interventions":[{"type":"DRUG","name":"Lithium carbonate","otherNames":[]},{"type":"DRUG","name":"Valproate","otherNames":["Depakote"]},{"type":"DRUG","name":"Risperidone","otherNames":["Risperdal"]}],"arms":[{"label":"1","type":"EXPERIMENTAL"},{"label":"2","type":"EXPERIMENTAL"},{"label":"3","type":"EXPERIMENTAL"}],"summary":"This study will evaluate the effectiveness of the medications, lithium (Eskalith®), valproate (Depakote®), and risperidone (Risperdal®) in treating children and adolescents with bipolar disorder or symptoms of mania.","primaryOutcome":{"measure":"Clinical Global Impressions-Bipolar Mania Improvement","timeFrame":"Measured at Week 8","effectByArm":[{"arm":"Randomized Medication - Lithium","deltaMin":2.49,"sd":1.05},{"arm":"Randomized Medication - Divalproex Sodium","deltaMin":2.73,"sd":1.08},{"arm":"Randomized Medication - Risperidone","deltaMin":1.7,"sd":0.63}],"pValues":[]},"eligibility":{"minAge":"6 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":7},"locations":{"siteCount":5,"countries":["United States"]},"refs":{"pmids":["18199241","22213771","26598476","26598475","22917200","17335331"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":6,"n":137},"commonTop":[]}}